𝔖 Bobbio Scriptorium

✦ LIBER ✦

Secukinumab reduces C-reactive protein levels in patients with moderate to severe plaque psoriasis: Result of a regimen-finding study

Book ID: 122622628
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 46 KB
Volume: 68
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2012.12.875

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adalimumab reduces C-reactive protein le

Adalimumab reduces C-reactive protein levels in patients with moderate to severe psoriasis

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Effect of secukinumab, a fully human ant

Effect of secukinumab, a fully human anti–interleukin-17a monoclonal antibody on C-reactive protein levels in patients with moderate to severe plaque psoriasis: Result of a dose-ranging study

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Secukinumab induction and maintenance th

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study

✍ Rich, P.; Sigurgeirsson, B.; Thaci, D.; Ortonne, J.-P.; Paul, C.; Schopf, R.E.; 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB

Secukinumab efficacy and safety in subje

Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE)

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Secukinumab improves hand, foot and nail

Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial

✍ Paul, C.; Reich, K.; Gottlieb, A.B.; Mrowietz, U.; Philipp, S.; Nakayama, J.; Ha 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB

Efficacy and safety results of secukinum

Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB